Cargando…

A risk score based on real-world data to predict early death in acute promyelocytic leukemia

With increasingly effective treatments, early death (ED) has become the predominant reason for therapeutic failure in patients with acute promyelocytic leukemia (APL). To better prevent ED, patients with high-risk of ED must be identified. Our aim was to develop a score that predicts the risk of ED...

Descripción completa

Detalles Bibliográficos
Autores principales: Österroos, Albin, Maia, Tânia, Eriksson, Anna, Jädersten, Martin, Lazarevic, Vladimir, Wennström, Lovisa, Antunovic, Petar, Cammenga, Jörg, Deneberg, Stefan, Lorenz, Fryderyk, Möllgård, Lars, Uggla, Bertil, Ölander, Emma, Aguiar, Eliana, Trigo, Fernanda, Höglund, Martin, Juliusson, Gunnar, Lehmann, Sören
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244824/
https://www.ncbi.nlm.nih.gov/pubmed/35081688
http://dx.doi.org/10.3324/haematol.2021.280093
_version_ 1784738609090265088
author Österroos, Albin
Maia, Tânia
Eriksson, Anna
Jädersten, Martin
Lazarevic, Vladimir
Wennström, Lovisa
Antunovic, Petar
Cammenga, Jörg
Deneberg, Stefan
Lorenz, Fryderyk
Möllgård, Lars
Uggla, Bertil
Ölander, Emma
Aguiar, Eliana
Trigo, Fernanda
Höglund, Martin
Juliusson, Gunnar
Lehmann, Sören
author_facet Österroos, Albin
Maia, Tânia
Eriksson, Anna
Jädersten, Martin
Lazarevic, Vladimir
Wennström, Lovisa
Antunovic, Petar
Cammenga, Jörg
Deneberg, Stefan
Lorenz, Fryderyk
Möllgård, Lars
Uggla, Bertil
Ölander, Emma
Aguiar, Eliana
Trigo, Fernanda
Höglund, Martin
Juliusson, Gunnar
Lehmann, Sören
author_sort Österroos, Albin
collection PubMed
description With increasingly effective treatments, early death (ED) has become the predominant reason for therapeutic failure in patients with acute promyelocytic leukemia (APL). To better prevent ED, patients with high-risk of ED must be identified. Our aim was to develop a score that predicts the risk of ED in a real-life setting. We used APL patients in the population-based Swedish AML Registry (n=301) and a Portuguese hospital-based registry (n=129) as training and validation cohorts, respectively. The cohorts were comparable with respect to age (median, 54 and 53 years) and ED rate (19.6% and 18.6%). The score was developed by logistic regression analyses, risk-per-quantile assessment and scoring based on ridge regression coefficients from multivariable penalized logistic regression analysis. White blood cell count, platelet count and age were selected by this approach as the most significant variables for predicting ED. The score identified low-, high- and very high-risk patients with ED risks of 4.8%, 20.2% and 50.9% respectively in the training cohort and with 6.7%, 25.0% and 36.0% as corresponding values for the validation cohort. The score identified an increased risk of ED already at sub-normal and normal white blood cell counts and, consequently, it was better at predicting ED risk than the Sanz score (AUROC 0.77 vs. 0.64). In summary, we here present an externally validated and population-based risk score to predict ED risk in a real-world setting, identifying patients with the most urgent need of aggressive ED prevention. The results also suggest that increased vigilance for ED is already necessary at sub-normal/normal white blood cell counts.
format Online
Article
Text
id pubmed-9244824
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-92448242022-07-07 A risk score based on real-world data to predict early death in acute promyelocytic leukemia Österroos, Albin Maia, Tânia Eriksson, Anna Jädersten, Martin Lazarevic, Vladimir Wennström, Lovisa Antunovic, Petar Cammenga, Jörg Deneberg, Stefan Lorenz, Fryderyk Möllgård, Lars Uggla, Bertil Ölander, Emma Aguiar, Eliana Trigo, Fernanda Höglund, Martin Juliusson, Gunnar Lehmann, Sören Haematologica Article - Acute Myeloid Leukemia With increasingly effective treatments, early death (ED) has become the predominant reason for therapeutic failure in patients with acute promyelocytic leukemia (APL). To better prevent ED, patients with high-risk of ED must be identified. Our aim was to develop a score that predicts the risk of ED in a real-life setting. We used APL patients in the population-based Swedish AML Registry (n=301) and a Portuguese hospital-based registry (n=129) as training and validation cohorts, respectively. The cohorts were comparable with respect to age (median, 54 and 53 years) and ED rate (19.6% and 18.6%). The score was developed by logistic regression analyses, risk-per-quantile assessment and scoring based on ridge regression coefficients from multivariable penalized logistic regression analysis. White blood cell count, platelet count and age were selected by this approach as the most significant variables for predicting ED. The score identified low-, high- and very high-risk patients with ED risks of 4.8%, 20.2% and 50.9% respectively in the training cohort and with 6.7%, 25.0% and 36.0% as corresponding values for the validation cohort. The score identified an increased risk of ED already at sub-normal and normal white blood cell counts and, consequently, it was better at predicting ED risk than the Sanz score (AUROC 0.77 vs. 0.64). In summary, we here present an externally validated and population-based risk score to predict ED risk in a real-world setting, identifying patients with the most urgent need of aggressive ED prevention. The results also suggest that increased vigilance for ED is already necessary at sub-normal/normal white blood cell counts. Fondazione Ferrata Storti 2022-01-27 /pmc/articles/PMC9244824/ /pubmed/35081688 http://dx.doi.org/10.3324/haematol.2021.280093 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article - Acute Myeloid Leukemia
Österroos, Albin
Maia, Tânia
Eriksson, Anna
Jädersten, Martin
Lazarevic, Vladimir
Wennström, Lovisa
Antunovic, Petar
Cammenga, Jörg
Deneberg, Stefan
Lorenz, Fryderyk
Möllgård, Lars
Uggla, Bertil
Ölander, Emma
Aguiar, Eliana
Trigo, Fernanda
Höglund, Martin
Juliusson, Gunnar
Lehmann, Sören
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
title A risk score based on real-world data to predict early death in acute promyelocytic leukemia
title_full A risk score based on real-world data to predict early death in acute promyelocytic leukemia
title_fullStr A risk score based on real-world data to predict early death in acute promyelocytic leukemia
title_full_unstemmed A risk score based on real-world data to predict early death in acute promyelocytic leukemia
title_short A risk score based on real-world data to predict early death in acute promyelocytic leukemia
title_sort risk score based on real-world data to predict early death in acute promyelocytic leukemia
topic Article - Acute Myeloid Leukemia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244824/
https://www.ncbi.nlm.nih.gov/pubmed/35081688
http://dx.doi.org/10.3324/haematol.2021.280093
work_keys_str_mv AT osterroosalbin ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT maiatania ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT erikssonanna ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT jaderstenmartin ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT lazarevicvladimir ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT wennstromlovisa ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT antunovicpetar ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT cammengajorg ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT denebergstefan ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT lorenzfryderyk ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT mollgardlars ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT ugglabertil ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT olanderemma ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT aguiareliana ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT trigofernanda ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT hoglundmartin ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT juliussongunnar ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT lehmannsoren ariskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT osterroosalbin riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT maiatania riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT erikssonanna riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT jaderstenmartin riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT lazarevicvladimir riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT wennstromlovisa riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT antunovicpetar riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT cammengajorg riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT denebergstefan riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT lorenzfryderyk riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT mollgardlars riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT ugglabertil riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT olanderemma riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT aguiareliana riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT trigofernanda riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT hoglundmartin riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT juliussongunnar riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia
AT lehmannsoren riskscorebasedonrealworlddatatopredictearlydeathinacutepromyelocyticleukemia